[go: up one dir, main page]

NO20015932D0 - Fremgangsmåte til å behandle diabetes - Google Patents

Fremgangsmåte til å behandle diabetes

Info

Publication number
NO20015932D0
NO20015932D0 NO20015932A NO20015932A NO20015932D0 NO 20015932 D0 NO20015932 D0 NO 20015932D0 NO 20015932 A NO20015932 A NO 20015932A NO 20015932 A NO20015932 A NO 20015932A NO 20015932 D0 NO20015932 D0 NO 20015932D0
Authority
NO
Norway
Prior art keywords
type
diabetes
symptoms
procedures
treating diabetes
Prior art date
Application number
NO20015932A
Other languages
English (en)
Other versions
NO324117B1 (no
NO20015932L (no
Inventor
Andreas Sommer
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of NO20015932D0 publication Critical patent/NO20015932D0/no
Publication of NO20015932L publication Critical patent/NO20015932L/no
Publication of NO324117B1 publication Critical patent/NO324117B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20015932A 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes. NO324117B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (3)

Publication Number Publication Date
NO20015932D0 true NO20015932D0 (no) 2001-12-04
NO20015932L NO20015932L (no) 2002-01-31
NO324117B1 NO324117B1 (no) 2007-08-27

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015932A NO324117B1 (no) 1999-06-04 2001-12-04 Anvendelse av et kompleks omfattende IGF-I/IGFBP-3 til a fremstille et legemiddel til a behandle diabetes.

Country Status (15)

Country Link
US (1) US6040292A (no)
EP (1) EP1183042B1 (no)
JP (1) JP2003501397A (no)
KR (1) KR100694737B1 (no)
CN (1) CN1235637C (no)
AT (1) ATE271880T1 (no)
AU (1) AU780400B2 (no)
CA (1) CA2373281C (no)
DE (1) DE60012517T2 (no)
ES (1) ES2222208T3 (no)
IL (1) IL146868A0 (no)
MX (1) MXPA01013384A (no)
NO (1) NO324117B1 (no)
WO (1) WO2000074710A2 (no)
ZA (1) ZA200110408B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TWI322153B (en) * 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
CA2422625A1 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
CA2592848C (en) * 2004-12-30 2014-06-17 Hill's Pet Nutrition, Inc. Compositions for feline consumption
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
US8404639B2 (en) 2008-10-29 2013-03-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
UA105384C2 (ru) 2009-04-01 2014-05-12 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
KR101847669B1 (ko) * 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
CA2132871A1 (en) * 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
PT723453E (pt) * 1993-08-03 2000-07-31 Celtrix Pharma Metodo de tratamento de desordens reprodutoras
ES2241906T3 (es) * 1993-09-20 2005-11-01 Celtrix Pharmaceuticals, Inc. Tratamiento de trastornos inmunologicos y hematologicos con igfbp solo o asociado con igf.
WO1995013824A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering igf-i and igfbp-3
WO1995013823A1 (en) * 1993-11-15 1995-05-26 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
CA2195474A1 (en) * 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
ATE271880T1 (de) 2004-08-15
AU780400B2 (en) 2005-03-17
CA2373281A1 (en) 2000-12-14
AU5041100A (en) 2000-12-28
JP2003501397A (ja) 2003-01-14
IL146868A0 (en) 2002-08-14
NO324117B1 (no) 2007-08-27
MXPA01013384A (es) 2003-09-04
KR100694737B1 (ko) 2007-03-14
US6040292A (en) 2000-03-21
CN1387440A (zh) 2002-12-25
ES2222208T3 (es) 2005-02-01
KR20020020723A (ko) 2002-03-15
ZA200110408B (en) 2003-03-19
DE60012517T2 (de) 2005-08-04
WO2000074710A2 (en) 2000-12-14
DE60012517D1 (de) 2004-09-02
EP1183042B1 (en) 2004-07-28
CA2373281C (en) 2010-01-12
EP1183042A2 (en) 2002-03-06
WO2000074710A3 (en) 2001-06-28
NO20015932L (no) 2002-01-31
HK1044895A1 (en) 2002-11-08
CN1235637C (zh) 2006-01-11

Similar Documents

Publication Publication Date Title
NO20015932L (no) Fremgangsmåte til å behandle diabetes
PT1409006E (pt) Misturas monodispersas e métodos de tratamento de diabetes
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
NO20003051L (no) Metode for administrering av AspB28-humant insulin
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
AU6323001A (en) Treatment of acute coronary syndrome with glp-1
JP2003521528A5 (no)
NO20052348L (no) Behandling av hemoragisk sjokk
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists
GB9818650D0 (en) Therapeutic compounds and methods of making and using the same
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
UA72871C2 (uk) Засіб для лікування та профілактики цукрового діабету та спосіб лікування
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos
ECSP982534A (es) Nuevo metodo de tratamiento

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees